Trexquant Investment LP Reduces Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL)

Trexquant Investment LP lowered its position in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 27.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 194,592 shares of the company's stock after selling 71,879 shares during the period. Trexquant Investment LP owned 0.28% of Replimune Group worth $2,357,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in REPL. Charles Schwab Investment Management Inc. raised its holdings in Replimune Group by 12.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company's stock worth $5,313,000 after purchasing an additional 52,498 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Replimune Group by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company's stock worth $15,657,000 after buying an additional 217,308 shares during the period. Barclays PLC increased its stake in shares of Replimune Group by 165.5% in the 3rd quarter. Barclays PLC now owns 158,491 shares of the company's stock worth $1,738,000 after acquiring an additional 98,791 shares in the last quarter. Victory Capital Management Inc. purchased a new position in Replimune Group during the 4th quarter valued at about $543,000. Finally, State Street Corp boosted its stake in Replimune Group by 102.1% during the third quarter. State Street Corp now owns 2,340,042 shares of the company's stock worth $25,647,000 after acquiring an additional 1,182,181 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on REPL. HC Wainwright raised their target price on shares of Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. BMO Capital Markets lifted their price objective on Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. boosted their target price on Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Replimune Group currently has an average rating of "Buy" and a consensus target price of $19.43.

Replimune Group Stock Performance

Shares of NASDAQ:REPL traded up $0.43 during midday trading on Friday, reaching $7.35. 765,455 shares of the company's stock traded hands, compared to its average volume of 868,498. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. Replimune Group, Inc. has a one year low of $4.92 and a one year high of $17.00. The company has a market cap of $566.06 million, a price-to-earnings ratio of -2.39 and a beta of 1.26. The stock has a 50 day moving average of $11.34 and a 200 day moving average of $11.88.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). As a group, equities research analysts anticipate that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.